Loading clinical trials...
Loading clinical trials...
A Phase III, Double-blind, Randomized, Study to Compare: 1) the Immunogenicity and Safety of 3 Commercial Scale Consistency Lots of GlaxoSmithKline (GSK) Biologicals' Herpes Simplex Candidate Vaccine in Healthy HSV-1 and -2 Seronegative (HSV 1-/2-) Female Subjects Aged 10 - 17 Years, and 2) Vaccine Immunogenicity in Healthy HSV 1-/2- Females Aged 10 - 17 Years With Healthy HSV 1-/2- Adult Females
Conditions
Interventions
GSK208141 vaccine
Locations
13
United States
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Fountain Valley, California, United States
GSK Investigational Site
Golden, Colorado, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Galveston, Texas, United States
Start Date
December 1, 2003
Primary Completion Date
September 1, 2005
Completion Date
January 1, 2006
Last Updated
September 21, 2016
NCT04065971
NCT05429346
NCT03282916
NCT05226949
NCT03626376
NCT00000635
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions